立体定向消融放疗治疗寡转移性肝细胞癌的疗效:一项II期研究
这项II期前瞻性研究纳入40例原发灶控制、1-5个可SABR的寡转移性肝细胞癌患者,2021-2022年对62个病灶行SABR。中位随访15.5个月,2年OS为80%,中位PFS 5.3个月,2年局部进展时间91.1%,无3级以上毒性。
要点
- SABR对寡转移性肝细胞癌局部控制好,2年局部进展时间达91.1%。
- 中位随访15.5个月,2年OS 80%,中位PFS 5.3个月。
- 无3级以上毒性,生活质量评分总体稳定。
核心结论
- SABR是寡转移性肝细胞癌有效且可行的选择,局部肿瘤控制极佳并改善生存,不负面影响生活质量。
- 原发灶控制后至寡转移出现时间较晚和甲胎蛋白较低的患者生存结局更好。
研究设计与样本
- II期前瞻性研究,纳入原发灶控制且1-5个可SABR转移灶的寡转移性肝细胞癌患者。
- 共40例连续患者于2021至2022年接受SABR,治疗62个病灶。
- 主要终点为总生存(OS)和无进展生存(PFS),次要终点包括局部进展时间、客观缓解率、疾病控制率、毒性和生活质量(EORTC QLQ-C30)。
- 临床试验注册号NCT05173610。
主要发现
- 寡转移最常见部位为肺(48.4%)、淋巴结(22.6%)和骨(17.7%)。
- 中位随访15.5个月,2年OS为80%,中位PFS为5.3个月,1年和2年PFS率分别为21.2%和0%。
- 原发灶控制后至寡转移出现时间较短与PFS独立相关(p=0.039,风险比2.127),年龄、Child-Pugh分级和甲胎蛋白亦与PFS相关(p分别为0.002、0.004、0.019)。
- 2年局部进展时间、客观缓解率和疾病控制率分别为91.1%、75.8%和98.4%。
- 10%患者出现急性毒性,7.5%出现晚期毒性,无3级以上毒性;所有生活质量评分保持稳定,未接受全身治疗的患者失眠和社会功能评分改善。
临床怎么用
- 作者认为SABR是寡转移性肝细胞癌有效且安全的治疗选择,无论肿瘤部位均能获得极佳局部控制并改善生存,不加重生活质量。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Stereotactic ablative radiotherapy (SABR) can extend survival and offers the potential for cure in some patients with oligometastatic disease (OMD). However, limited evidence exists regarding its use in oligometastatic hepatocellular carcinoma (HCC). We aimed to prospectively investigate the efficacy and safety of SABR in patients with oligometastatic HCC. METHODS: We enrolled patients with controlled primary HCC and one to five metastatic lesions amenable to SABR. The primary endpoint was treatment efficacy defined as overall survival (OS) and progression-free survival (PFS). The secondary endpoints included time to local progression, objective response rate, disease control rate, toxicities, and quality of life (QOL), assessed using the EORTC QLQ-C30 before, and 0, 1, and 3 months after SABR. RESULTS: Overall, 40 consecutive patients received SABR on 62 lesions between 2021 and 2022. The most common locations for OMD were the lungs (48.4%), lymph nodes (22.6%), and bone (17.7%). After a median follow-up of 15.5 months, the 2-year OS was 80%. Median PFS was 5.3 months, with 1- and 2-year PFS rates of 21.2% and 0%, respectively. A shorter time to OMD from the controlled primary independently correlated with PFS (p = 0.039, hazard ratio 2.127) alongside age, Child-Pugh class, and alpha-fetoprotein (p = 0.002, 0.004, 0.019, respectively). The 2-year time to local progression, objective response rate, and disease control rate were 91.1%, 75.8%, and 98.4%, respectively. Overall, 10% of patients experienced acute toxicity, and 7.5% experienced late toxicity, with no grade 3+ toxicity. All QOL scores remained stable, whereas the patients without systemic treatments had improved insomnia and social functioning scores. CONCLUSIONS: SABR is an effective and feasible option for oligometastatic HCC that leads to excellent local tumor control and improves survival without adversely affecting QOL. IMPACT AND IMPLICATIONS: Stereotactic ablative radiotherapy (SABR) is a non-invasive treatment approach capable of efficiently ablating the target lesion; however, neither the oligometastatic disease concept nor the potential benefits of SABR have been well-defined in hepatocellular carcinoma (HCC). According to this study, SABR is an effective and safe treatment option for oligometastatic HCC, yielding excellent local tumor control and survival improvement without worsening patients' quality of life, regardless of tumor sites. We also demonstrated that patients with a later presentation of OMD from the controlled primary and lower alpha-fetoprotein levels achieved better survival outcomes. This is the first prospective study of SABR in oligometastatic HCC, providing insights for the development of novel strategies to improve oncologic outcomes. CLINICAL TRIAL NUMBER: NCT05173610.
引用
- Choi SH, Lee BM, Kim J, et al. Efficacy of stereotactic ablative radiotherapy in patients with oligometastatic hepatocellular carcinoma: A phase II study. J Hepatol. 2024. PMID: 38467379. doi:10.1016/j.jhep.2024.03.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。